This paper aims to compare the effects of three treatment modalities for a submacular hemorrhage (SMH) secondary to exudative age-related macular degeneration (AMD). Seventy-seven patients with an SMH were divided into three groups: small-sized (optic disc diameter (ODD) ≥ 1 to < 4), medium-sized (ODD ≥ 4 within the temporal arcade) and large-sized (ODD ≥ 4, exceeding the temporal arcade). Patients received anti-vascular endothelial growth factor (anti-VEGF) monotherapy, pneumatic displacement (PD) with anti-VEGF or a vitrectomy with a subretinal tissue plasminogen activator (tPA) and gas tamponade based on the surgeon’s discretion. The functional and anatomical outcomes were evaluated. Among the 77 eyes, 45 eyes had a small-sized, 21 eyes had a medium-sized and 11 eyes had a large-sized SMH. In the small-sized group, all treatment modalities showed a gradual best-corrected visual acuity (BCVA) improvement with high hemorrhagic regression or displacement rates (over 75%). In the medium-sized group, PD and surgery were associated with better BCVA with more displacement than anti-VEGF monotherapy (67% and 83%, respectively, vs. 33%). In the large-sized group, surgery showed a better visual improvement with a higher displacement rate than PD (86% vs. 25%). Our findings demonstrated that visual improvement can be expected through appropriate treatment strategy regardless of the SMH size. In cases with a larger SMH, invasive techniques including PD or surgery were more advantageous than anti-VEGF monotherapy.

Purpose—This study was conducted to develop an automated detection algorithm for screening fundus abnormalities, including age-related macular degeneration (AMD), diabetic retinopathy (DR), epiretinal membrane (ERM), retinal vascular occlusion (RVO), and suspected glaucoma among health screening program participants. Methods—The development dataset consisted of 43,221 retinal fundus photographs (from 25,564 participants, mean age 53.38 ± 10.97 years, female 39.0%) from a health screening program and patients of the Kangbuk Samsung Hospital Ophthalmology Department from 2006 to 2017. We evaluated our screening algorithm on independent validation datasets. Five separate one-versus-rest (OVR) classification algorithms based on deep convolutional neural networks (CNNs) were trained to detect AMD, ERM, DR, RVO, and suspected glaucoma. The ground truth for both development and validation datasets was graded at least two times by three ophthalmologists. The area under the receiver operating characteristic curve (AUC), sensitivity, and specificity were calculated for each disease, as well as their macro-averages. Results—For the internal validation dataset, the average sensitivity was 0.9098 (95% confidence interval (CI), 0.8660–0.9536), the average specificity was 0.9079 (95% CI, 0.8576–0.9582), and the overall accuracy was 0.9092 (95% CI, 0.8769–0.9415). For the external validation dataset consisting of 1698 images, the average of the AUCs was 0.9025 (95% CI, 0.8671–0.9379). Conclusions—Our algorithm had high sensitivity and specificity for detecting major fundus abnormalities. Our study will facilitate expansion of the applications of deep learning-based computer-aided diagnostic decision support tools in actual clinical settings. Further research is needed to improved generalization for this algorithm.

Purpose: We compared the efficacy of focal laser photocoagulation and intravitreal bevacizumab injection in the treatment of chronic central serous chorioretinopathy. Methods: We conducted a retrospective analysis involving 46 eyes of 46 patients with chronic central serous chorioretinopathy who received focal laser photocoagulation (22 eyes) or intravitreal bevacizumab injection (24 eyes). Changes in best-corrected visual acuity (BVCA), central macular thickness, and rates of complete subretinal fluid (SRF) resolution and recurrence were compared over a 6-month period. Results: Although the focal laser photocoagulation and intravitreal bevacizumab injection groups demonstrated a significant reduction in central macular thickness at 6 months (p < 0.001), no statistically significant differences were observed between these groups at the end of the follow-up period. Notably, a gradual improvement in BVCA was observed in both groups following initial treatment, with significant improvement seen at 6 months (p = 0.049 and p = 0.048 for the laser and injection groups, respectively). However, no statistically significant difference in BVCA improvement was observed between the groups. Complete SRF resolution was achieved in 22 eyes in the laser group and 23 eyes in the injection group. Although recurrence of SRF was observed in 9 and 13 eyes in the laser and injection groups, respectively, there was no statistically significant difference between the groups (p = 0.229). Conclusions: Focal laser photocoagulation and intravitreal bevacizumab injection significantly improved anatomical and visual acuity outcomes in patients with chronic central serous chorioretinopathy. Although focal laser photocoagulation was associated with more rapid visual recovery and a lower recurrence rate compared to intravitreal bevacizumab injection, further studies are needed to evaluate its potential complications.